A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
Clinical trial NCT02935686 · COMPLETED
Trial details
- NCT number
- NCT02935686
- Sponsor
- Janssen Vaccines & Prevention B.V.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-31
- Primary completion
- 2023-11-22
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.